Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review
- PMID: 20101751
- PMCID: PMC2930399
- DOI: 10.1002/hep.23384
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review
Abstract
Chronic hepatitis B (CHB) is major global health problem. In China, where about 120,000,000 persons are chronically infected, CHB has been treated for centuries with traditional Chinese medicines (TCMs). This review summarizes and meta-analyzes the results of randomized controlled trials (RCTs) of TCM formulations reported in China in 1998-2008 for treatment of CHB. RCTs comparing either TCM formulations alone or in combination with interferon (IFN) or lamivudine (LAM) versus IFN or LAM were included. Chinese electronic databases were searched. The methodological quality of RCTs was assessed using the Jadad scale. TCMs had a greater beneficial effect (P = 0.0003) than IFN and a slightly better effect (P = 0.01) than LAM on the normalization of serum alanine aminotransferase. TCMs had a similar beneficial effect when compared with IFN or LAM for CHB on antiviral activity as evidenced by the loss of serum hepatitis B e antigen and hepatitis B virus (HBV) DNA. TCMs enhanced IFN and LAM antiviral activities and improvements of liver function. The quality of many studies was poor; reports often lacked information regarding methods of randomization or blinding and adverse events.
Conclusion: Some TCMs seem effective as alternative remedies for patients with CHB, suggesting that further study of TCMs in the treatment of CHB is warranted, both in preclinical models of HBV infection and in higher quality RCTs worldwide.
Figures
Comment in
-
Methodological quality assessment for traditional Chinese medicine: CONSORT is better.Hepatology. 2011 Jun;53(6):2148-9. doi: 10.1002/hep.24126. Epub 2011 Apr 6. Hepatology. 2011. PMID: 21472741 No abstract available.
References
-
- Rizzetto M, Ciancio A. Chronic HBV-related liver disease. Mol Aspects Med. 2008;29:72–84. - PubMed
-
- Shan J. China has 120m hepatitis B carriers. China Daily. 2007
-
- McNeil DG., Jr. Blood pressure is most lethal in poor and middle-income countries. The New York Times. 2008 May 6;
-
- Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–1500. - PubMed
-
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical